Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma

Abstract

We have previously reported that Cezanne could be a prognostic biomarker for survival in hepatocellular carcinoma (HCC) patients. However, the role of Cezanne genes in HCC cells and its response to postoperative adjuvant transcatheter arterial chemoembolization (TACE) in HCC patients remains unknown. In this study, Cezanne expression was detected in human HCC using real-time PCR, western blot and immunohistochemistry. The function of Cezanne in HCC cells was determined by Transwell invasion assays and nude mice metastasis assay. The response of Cezanne in patients who received adjuvant TACE after hepatectomy was evaluated. Functional study demonstrated that interference of Cezanne expression promoted the migration and invasion of HCC cells in vitro and boosted metastasized HCC formation in mice. Upregulation of Cezanne diminished the adhesion and migration of hepatoma cells. Further study indicated that Cezanne might inhibit invasion of HCC cells by inducing epithelial–mesenchymal transition (EMT). In addition, patients with low Cezanne expression had significant improvement in prognosis after receiving adjuvant TACE. In contrast, patients with high Cezanne expression had a poorer response to adjuvant TACE. Moreover, Cezanne status was associated with response to adjuvant TACE in patients subgroup stratified by vascular invasion, tumor size and tumor number. In conclusion, Cezanne may be a novel antioncogene that has a pivotal role in the invasion of HCC and contribute to the selection of patients who may benefit from adjuvant TACE to prevent recurrence.

MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression

“…What's more, from the estimated data, the incidence of HCC will rise faster than any other tumors in the U.S.A. in 2019 [1]. HCC is a highly malignant tumor with a high frequency of metastasis and recurrence, which also make it one of the most lethal tumors in the world [4,5]. Every year, HCC will take a large amount of burden in the public health expenditure, therefore it is very essential for us to deeply study the biomarkers related to the progression of HCC and provide novel therapies for better treatments of HCC.…”

<p>ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance</p>

“…[49][50][51] Various local therapeutic strategies including radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) can delay the disease progression and reduce the tumor burden of advanced HCC, but the recurrence of the malignancy after treatment has made treating options even narrower. [52][53][54][55] These situations make chemotherapies important for advanced HCC treatment. Advanced HCC is insensitive to traditional cytotoxic chemotherapies and is featured to have MDR.…”

The prognostic significance and regulatory networks of DAP3 in hepatocellular carcinoma microenvironment based on bioinformatics analysis

“…Liver cancer is one of the most common malignant tumors and the fourth leading cause of cancer-related deaths worldwide, threatening human health and life seriously [1,2]. Hepatocellular carcinoma (HCC) is a common type of liver cancer, accounting for almost 90% [3,4]. The major risk factors, which develop HCC, are excessive alcohol intake and virus infection, including hepatitis B or C. Although HCC patients for early detection have an access to various treatments, such as surgery, liver transplantation and radiation, the therapeutics for patients with advanced stages are not effective and the prognosis of advanced HCC patients is signi cantly poor, with a low 5-year survival rate under the level of 5%.…”